CWBR - CohBar: A Promising Early Pureplay On Mitochondrial-Based Therapeutics
- CohBar, Inc. is an interesting early-clinical-stage biotechnology company developing mitochondrial-based therapeutics for treating chronic and age-related diseases including nonalcoholic steatohepatitis and obesity, amongst others.
- CohBar's pipeline consists of the lead compound, CB4211, which is in a Phase 1b and Phase 1a/1b for NASH and Obesity, respectively, and four other pre-clinical mitochondrial-based programs.
- CohBar is in a reasonable financial position with funding for 1-2 years based on a 2020 cash burn of -$10M and cash worth $21M though not revenue-producing till 2025.
- CohBar's next major catalyst will be 2Q 2021's CB4211's Phase 1b critical top-line data announcement which will be quite defining for their pipeline and science.
- In summary, the author projects CohBar, Inc. as a medium-to-long-term "buy" with a critical inflection point being 2Q 2021's topline announcement.
For further details see:
CohBar: A Promising Early Pureplay On Mitochondrial-Based Therapeutics